To clarify the role of the intermediate filament protein vimentin in the epithelial-to-mesenchymal transition (EMT), we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the drug ALD-R491, which targets vimentin. This evidence concerns the gene VIM and lung carcinoma.